Subtopic Deep Dive
Pseudomyxoma Peritonei
Research Guide
What is Pseudomyxoma Peritonei?
Pseudomyxoma peritonei (PMP) is a clinical syndrome characterized by accumulation of mucinous ascites in the peritoneum originating from appendiceal mucinous neoplasms.
PMP research focuses on cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment. Chua et al. (2012) reported long-term survival data from 2298 patients across 16 centers (1029 citations). Sugarbaker (2005) proposed CRS/HIPEC as a new standard for appendiceal neoplasms and PMP (655 citations).
Why It Matters
CRS/HIPEC transforms PMP from a fatal disease with median survival under 1 year to a manageable condition with 5-year survival rates up to 63% in low-grade cases (Chua et al., 2012). Multi-institutional data show complete cytoreduction (CC-0/1) as the strongest prognostic factor (Chua et al., 2012; Sugarbaker, 2005). Population studies highlight PMP's rarity but high CRS/HIPEC success compared to other peritoneal carcinomatoses (Thomassen et al., 2013). These outcomes guide patient selection and surgical protocols worldwide.
Key Research Challenges
Heterogeneous Tumor Biology
PMP ranges from low-grade mucinous carcinoma peritonei to high-grade with signet-ring cells, complicating prognosis and treatment (Chua et al., 2012). Grading systems like Ronnett and PSOGI vary in reproducibility. Optimal chemotherapy regimens differ by grade (Sugarbaker, 2005).
Achieving Complete Cytoreduction
Complete cytoreduction (CC-0/1) correlates with survival but succeeds in only 50-70% of cases due to disease extent (Chua et al., 2012). Peritoneal Cancer Index (PCI) >20 predicts poor outcomes. HIPEC drug selection (mitomycin-C vs. oxaliplatin) remains debated (Yang et al., 2011).
Long-Term Recurrence Patterns
Recurrence occurs in 20-30% of optimally treated patients after 5-10 years, requiring surveillance strategies (Chua et al., 2012). Functional outcomes and quality-of-life data are limited post-CRS/HIPEC. Repeat CRS feasibility needs multi-institutional validation (Gléhen et al., 2010).
Essential Papers
Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Terence C. Chua, Brendan Moran, Paul H. Sugarbaker et al. · 2012 · Journal of Clinical Oncology · 1.0K citations
Purpose Pseudomyxoma peritonei (PMP) originating from an appendiceal mucinous neoplasm remains a biologically heterogeneous disease. The purpose of our study was to evaluate outcome and long-term s...
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial
Xiaojun Yang, Chaoqun Huang, Tao Suo et al. · 2011 · Annals of Surgical Oncology · 675 citations
For synchronous gastric PC, CRS + HIPEC with mitomycin C 30 mg and cisplatin 120 mg may improve survival with acceptable morbidity.
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience
Tristan D. Yan, Marcello Deraco, Dario Baratti et al. · 2009 · Journal of Clinical Oncology · 675 citations
Purpose This multi-institutional registry study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (...
New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
Paul H. Sugarbaker · 2005 · The Lancet Oncology · 655 citations
Peritoneal carcinomatosis of gastric origin: A population‐based study on incidence, survival and risk factors
Irene Thomassen, Yvette R. van Gestel, Bert van Ramshorst et al. · 2013 · International Journal of Cancer · 575 citations
Peritoneal carcinomatosis (PC) is an important cause of morbidity and mortality among patients with gastric cancer. The aim of the current study was to provide reliable population‐based data on the...
Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy
Olivier Gléhen, François Noël Gilly, Florent Boutitie et al. · 2010 · Cancer · 507 citations
Abstract BACKGROUND: Peritoneal carcinomatosis (PC) from nonovarian malignancies long has been regarded as a terminal disease. Over the past decade, new locoregional therapeutic approaches combinin...
Mucosal hyperplasia, mucinous cystadenoma, and mucinous cystadenocarcinoma of the appendix.A re-evaluation of appendiceal “mucocele”
Enrique Higa, Juan Rosaí, Carlos A. Pizzimbono et al. · 1973 · Cancer · 496 citations
The evaluation of 73 appendiceal lesions fulfilling the criteria of so-called "mucocele" showed that they comprise 3. distinctive clinicopathologic entities: 1) Focal or diffuse mucosal hyperplasia...
Reading Guide
Foundational Papers
Start with Chua et al. (2012; 1029 citations) for multi-center CRS/HIPEC survival benchmarks in 2298 PMP patients, then Sugarbaker (2005; 655 citations) for treatment standardization rationale, followed by Higa et al. (1973; 496 citations) for appendiceal mucocele histopathology foundations.
Recent Advances
Yang et al. (2011; 675 citations) details HIPEC regimens for peritoneal disease; Thomassen et al. (2013; 575 citations) provides population-based PC incidence data contextualizing PMP rarity.
Core Methods
Core techniques: CRS peritonectomy procedures, HIPEC with mitomycin-C 30mg + cisplatin 120mg (Yang et al., 2011), PCI tumor burden scoring, completeness of cytoreduction (CC-0/1) assessment (Chua et al., 2012).
How PapersFlow Helps You Research Pseudomyxoma Peritonei
Discover & Search
Research Agent uses searchPapers('pseudomyxoma peritonei CRS HIPEC survival') to retrieve Chua et al. (2012) with 1029 citations, then citationGraph reveals Sugarbaker (2005) as a foundational node linking 655-cited standard-of-care paper to 50+ related works. findSimilarPapers expands to PSOGI registry studies; exaSearch uncovers recent HIPEC protocol variants.
Analyze & Verify
Analysis Agent applies readPaperContent on Chua et al. (2012) to extract PCI-survival curves, then runPythonAnalysis with pandas fits Kaplan-Meier models from 2298-patient data for GRADE A evidence verification. verifyResponse (CoVe) cross-checks survival claims against Thomassen et al. (2013) population data, flagging discrepancies in gastric PC vs. PMP outcomes.
Synthesize & Write
Synthesis Agent detects gaps in high-grade PMP HIPEC regimens via contradiction flagging between Yang et al. (2011) mitomycin-cisplatin and Gléhen et al. (2010) protocols. Writing Agent uses latexEditText for surgical workflow diagrams, latexSyncCitations integrates 10 core papers, and latexCompile generates submission-ready review with exportMermaid for PCI scoring flowcharts.
Use Cases
"Analyze survival curves from Chua 2012 PMP dataset and compare to PSOGI benchmarks"
Research Agent → searchPapers → readPaperContent (Chua et al. 2012) → Analysis Agent → runPythonAnalysis (pandas Kaplan-Meier plotting, NumPy hazard ratios) → matplotlib survival plot with statistical p-values.
"Write LaTeX review section on PMP CRS/HIPEC protocols citing Chua 2012 and Sugarbaker 2005"
Synthesis Agent → gap detection → Writing Agent → latexEditText (protocol text) → latexSyncCitations (10 papers) → latexCompile → PDF with auto-generated bibliography.
"Find open-source code for Peritoneal Cancer Index (PCI) calculator from PMP surgical papers"
Research Agent → paperExtractUrls (Sugarbaker 2005) → paperFindGithubRepo → Code Discovery → githubRepoInspect → validated PCI Python scorer forked from PSOGI-linked repo.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ PMP papers: searchPapers → citationGraph → DeepScan 7-step analysis with GRADE grading on Chua et al. (2012) survival data → structured report. DeepScan verifies HIPEC morbidity claims across Yang et al. (2011) and Gléhen et al. (2010) via CoVe checkpoints. Theorizer generates hypotheses on mucin-production molecular targets from Higa et al. (1973) pathology integrated with modern CRS outcomes.
Frequently Asked Questions
What defines Pseudomyxoma Peritonei?
PMP is intraperitoneal mucinous ascites from ruptured appendiceal mucinous neoplasms, classified as low-grade (disseminated peritoneal adenomucinosis) or high-grade (peritoneal mucinous carcinomatosis) per Ronnett criteria (Chua et al., 2012).
What are standard treatment methods?
CRS to achieve CC-0/1 resection combined with HIPEC using mitomycin-C is standard, achieving 63% 10-year survival in low-grade PMP (Chua et al., 2012). PCI scoring guides resectability (Sugarbaker, 2005).
What are key papers on PMP outcomes?
Chua et al. (2012; 1029 citations) reports PSOGI registry data on 2298 patients post-CRS/HIPEC. Sugarbaker (2005; 655 citations) establishes CRS/HIPEC as new standard for appendiceal PMP.
What open problems remain in PMP research?
High-grade PMP response to HIPEC is suboptimal (median survival 25 months); molecular biomarkers for recurrence prediction are lacking (Chua et al., 2012). Repeat CRS protocols need randomized trial validation.
Research Intraperitoneal and Appendiceal Malignancies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pseudomyxoma Peritonei with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers